Diabetes

Dapagliflozin’s CV Effects Consistent Across Baseline Kidney Function

Publish Date April 15, 2021

Reductions in cardiovascular risk associated with dapagliflozin treatment in patients with type 2 diabetes are most pronounced in those who have both reduced kidney function and albuminuria, a recent analysis shows.

De Novo Hyperkalemia Increases Risks for Death, Hospitalizations

Publish Date April 15, 2021

Even a single episode of hyperkalemia is associated with a major disease burden, a study finds.

Diabetes Tied to Mortality, CV Events in Chronic Coronary Syndrome

Publish Date April 15, 2021

Diabetes linked to increased risks for primary outcome of cardiovascular death, MI, stroke and secondary outcomes

Type 2 Diabetes Tied to Higher Risk for Parkinson Disease

Publish Date April 13, 2021

Additionally, among patients with Parkinson disease, type 2 diabetes tied to more rapid Parkinson progression

Ozempic Injection 1mg Now Available as a Single Monthly Pen

Publish Date April 13, 2021

Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.

ENDO: Continuing Semaglutide Aids Weight Loss in Overweight, Obese

Publish Date April 12, 2021

Maintaining treatment resulted in continued weight loss during additional 48 weeks compared with switching to placebo.

SGLT2 Inhibitor Use Linked to Reduced Risk of Atrial Arrhythmias in T2DM Patients

Publish Date April 6, 2021

This meta-analysis aimed to determine the association between SGLT2i use and arrhythmias in patients with T2DM or HF.

Women No More Likely to Use Contraception After Diabetes Diagnosis

Publish Date April 6, 2021

Prescriptions for short-acting hormonal methods, such as pills and injections, declined in the year after diabetes diagnosis

Zegalogue Approved for Severe Hypoglycemia in Patients With Diabetes

Publish Date April 5, 2021

Zegalogue is a glucagon analogue that is formulated in a ready-to-use aqueous solution for subcutaneous administration.

Lifestyle Changes May Up CVD Risk in Some T2DM Patients

Publish Date April 1, 2021

Intensive lifestyle intervention may be detrimental for overweight, obese patients with type 2 diabetes who have poor glycemic control